Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
Traditionally, science is connected to the patient. We want to connect patients to science. This is the business model of today and tomorrow”. Jean-Christophe Tellier, CEO at UCB #UCB90 https://t.co/Zt19yEbo5e https://t.co/hzQVuL97s6
— UCB News (@ucb_news) 22.01.2019 -
UCB celebrated its 90th birthday last year. As we look ahead to the next 90 years, we continue to be inspired by patients and driven by science! #UCB90 #InspiredByPatients #DrivenByScience https://t.co/6VcRA3lpGT https://t.co/GHNa1t7IaY
— UCB News (@ucb_news) 18.01.2019 -
Media: UCB and @Amgen announce positive vote from @US_FDA advisory committee for potential new #osteoporosis treatment https://t.co/roadh9Rbr1 https://t.co/6h0m6D9l0g
— UCB News (@ucb_news) 17.01.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
